ISLET GRAFTS IN SERTOLI CELL IMMUNOPRIVILEGED SITES

支持细胞免疫特权位点的胰岛移植物

• 批准号: 2017780
• 负责人: HELENA P SELAWRY
• 金额: $ 9.95万
• 依托单位: SERTOLI TECHNOLOGIES, INC.
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-03-01 至 1997-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2017780
• 关键词: Sertoli cells; cell transplantation; diabetes mellitus therapy; disease /disorder model; embryo /fetus tissue transplantation; immunosuppression; immunosuppressive; insulin dependent diabetes mellitus; laboratory rat; newborn animals; pancreatic islet transplantation; reproductive tissue transplantation; swine; transplantation immunology; xenotransplantation

Type I diabetes and its complications is a tremendous cost to the health care system. Implementing islet transplantation to enable patients to regain physiological control of their blood glucose levels faces two major obstacles: lack of human donor pancreases and graft rejection. Use of animal cells or tissues and immunosuppression could ameliorate these problems, but introduce additional problems, particularly chronic administration of toxic immunosuppressive agents. Sertoli Technologies, Inc. is developing a diabetes cellular therapy and product based on Sertoli cell and islet xenografts that provides limited and localized, not systemic, immunosuppression and enhanced growth of engrafted tissue. The proposed development systematically builds on our initial experience with our chosen Sertoli cell and islet source, establishes quality criteria for the cells, demonstrates the efficacy of the therapy in chemically-induced and autoimmune diabetic rodents, explores immunosuppression options, transplant sites and the effect of pretolerization and estimates a cell dose-response relationship. These data will establish our commercial product, satisfy regulatory concerns and enable future safety and efficacy studies in higher animals as a prelude to initiation of xenotransplantation in type I diabetic patients.

1型糖尿病及其并发症是一个巨大的健康成本